November 24, 2014
In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement from phase 1 to phase 2 trials
SEATTLE, Nov. 24, 2014 /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed.
November 18, 2014
Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design
SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine &